A note on scope before the analysis begins: the peer-reviewed knowledge base covering the April 2026 FDA-reclassified peptide stack includes BPC-157, TB-500, KPV, MOTS-c, Semax, Dihexa, and GHK-Cu. Five compounds listed in broader discussions of this stack — DSIP, LL-37, Epitalon, PEG-MGF, and Melanotan II — are not represented in the current research database. No evidence-based claims are made about them here.
Healing and Repair
BPC-157: Gastrointestinal and Musculoskeletal Tissue
BPC-157 (Body Protective Compound-157) carries one of the more comprehensive preclinical literature bases among synthetic peptides currently under regulatory scrutiny. In gastrointestinal contexts, it maintains mucosal integrity, counteracts colitis across multiple experimental models, and facilitates resolution of fistulas. The mechanistic picture includes contributions to prostaglandin-related repair pathways and adaptive cytoprotective processes across both the stomach and intestine. In short-bowel surgery models, BPC-157 administration produced consistent weight gain alongside measurable structural changes across all three intestinal wall layers — villus height, crypt depth, and muscular thickness.
The musculoskeletal data follow a similar pattern. In rodent tendon transection models, BPC-157 consistently improves functional indices, biomechanical strength, collagen organization, and early revascularization. Of particular note is its capacity to oppose corticosteroid-induced impairment of tendon healing — a finding with direct clinical relevance given how frequently corticosteroids are administered near tendon injury sites. At the cellular level, BPC-157 enhances tendon fibroblast survival under mechanical and chemical stress, promotes cell migration and proliferation, and upregulates growth hormone receptor expression on fibroblasts.
Myogenic activity is also documented. Following skeletal muscle injury, BPC-157 promotes muscle fiber regeneration, accelerates re-establishment of myotendinous junctions, and reduces fibrosis at repair sites. Osteogenic effects have been observed as well — fracture healing is promoted, including in conditions of avascular osteonecrosis and delayed union, though these findings remain confined to animal models.
TB-500 (Thymosin Beta-4): Wound Healing and Tissue Regeneration
TB-500's active molecule is Thymosin Beta-4 (Tβ4), a 43-amino-acid G-actin sequestering protein first isolated from bovine thymus. Its biological range is broad: wound healing, angiogenesis, inflammation modulation, and tissue regeneration across multiple tissue types have all been documented experimentally. The corneal wound healing data are among the most compelling, with Tβ4 significantly accelerating recovery after corneal injury — a finding that generated a formal clinical trial program under the designation RGN-259.
Beyond ocular tissue, Tβ4 has been characterized as a human exerkine and growth factor, with defined roles in angiogenesis promotion and hair follicle development. Its anti-aging regenerative potential has been acknowledged in the research literature, and active investigation into regenerative therapy applications continues. The transition from preclinical observation to confirmed human efficacy, however, remains incomplete for most of these endpoints.
GHK-Cu: Skin Regeneration and Collagen Synthesis
GHK-Cu (glycyl-L-histidyl-L-lysine-copper) is a naturally occurring tripeptide found in human blood serum, and the skin regeneration literature around it is unusually developed for a peptide of its size. It promotes collagen and elastin synthesis by increasing fibroblast activity through Smad and MAPK transcriptional pathways — meaning its effects operate at the level of gene expression, not merely surface interaction.
Clinical data offer some of the more concrete numbers in this field. A facial cream containing GHK-Cu, applied for 12 weeks in 71 women with mild-to-advanced photoaging, increased skin density and thickness, reduced laxity, improved clarity, and decreased fine line and wrinkle depth. A separate GHK-Cu eye cream outperformed both placebo and vitamin K cream at the same 12-week endpoint. In a comparison study on thigh skin, GHK-Cu improved collagen production in 70% of treated women — against 50% for vitamin C cream and 40% for retinoic acid.
The functional profile extends beyond aesthetics. GHK-Cu promotes angiogenesis, nerve growth, and DNA repair, accelerates wound healing, protects against UV radiation, and reduces markers of inflammation and oxidative damage. Conjugation with liposomes further enhances its utility by improving dermal penetration and inhibiting elastase — thereby reducing the rate of elastin degradation directly at the target tissue.
Brain and Mood
Semax: Neuroprotection and Cognitive Function
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic hexapeptide derived from the ACTH(4–10) fragment, developed specifically as a nootropic and neuroprotective agent without the hormonal activity of its parent molecule. It demonstrates nootropic, psychostimulating, antioxidant, and antihypoxic effects across experimental systems. Its most mechanistically robust finding is a significant increase in BDNF (brain-derived neurotrophic factor) expression in the rat hippocampus following administration — a finding with direct relevance to neuroplasticity and neuroprotection.
In ischemic stroke models, Semax reduces neurological deficits and improves survival. Clinical administration has been shown to increase BDNF plasma levels and accelerate both functional and motor recovery. Additional mechanisms include inhibition of nitric oxide synthesis, protection of neuronal cultures from oxidative stress and glutamate neurotoxicity, and anticoagulant properties. In Alzheimer's disease models, Semax and a related derivative reduced amyloid plaque burden in both cortex and hippocampus. The peptide also forms stable complexes with copper(II) ions and prevents copper-induced cytotoxicity in neuronal and endothelial cell lines — a finding that positions it at an interesting intersection of metal chelation and neuroprotective biology.
Dihexa: Synaptogenesis and Cognitive Rescue
Dihexa is an angiotensin IV analog developed originally to address cognitive decline in neurodegenerative disease. Its central mechanism involves potentiation of hepatocyte growth factor (HGF) signaling and stimulation of the c-Met receptor pathway — both directly implicated in synaptogenesis and neural remodeling. Preclinical studies have demonstrated restoration of memory function and enhanced synaptic connectivity in Alzheimer's disease models.
In APP/PS1 transgenic mice, Dihexa increased cortical neuron survival and elevated synaptophysin expression — synaptophysin being a key synaptic vesicle marker whose abundance reflects functional synaptic density. Cognitive rescue in these animals operated through the PI3K/AKT signaling pathway. The compound's capacity for augmented spinogenesis makes it a pharmacologically interesting candidate in any pathology where reduced synaptic connectivity is a defining feature. Procognitive properties have been confirmed in both scopolamine-induced and age-related cognitive deficit models, though human data remain absent from the current literature.
Immunity and Inflammation
KPV: Intestinal Inflammation and Barrier Function
KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH). Its anti-inflammatory mechanism is notable for being largely independent of melanocortin receptor signaling — that is, it does not require surface receptor binding to exert its primary effect. Instead, KPV acts intracellularly by reducing the duration of NF-κB activation through IκBα stabilization in the presence of pro-inflammatory cytokines. The predominant site of KPV accumulation following cellular uptake is the nucleus itself.
In DSS- and TNBS-induced colitis models, oral KPV decreased intestinal myeloperoxidase (MPO) activity by approximately 50% — MPO activity being a direct index of neutrophilic infiltration and acute inflammatory burden. At the immune cell level, KPV drives macrophage polarization away from the pro-inflammatory M1 phenotype toward the anti-inflammatory M2 phenotype, while simultaneously enhancing regulatory T cell (Treg) differentiation. Both shifts are central to tissue repair in inflammatory bowel conditions. KPV also reinforces intestinal barrier function by strengthening tight junction proteins, reducing luminal antigen penetration and the inflammatory cascade that follows. Systemic toxicity was not observed with daily administration over a seven-day period in these models, though longer-term safety data in humans are not established.
Anti-Aging and Metabolism
MOTS-c: Mitochondrial Signaling and Metabolic Longevity
MOTS-c is a mitochondrial-derived peptide (MDP) encoded within the mitochondrial genome — a distinction that places it in a mechanistically unique category relative to nuclear-encoded peptides. Its primary metabolic mechanism involves promoting biosynthesis of AICAR, an endogenous AMP analogue that activates AMPK (AMP-activated protein kinase), the master regulator of cellular energy homeostasis. AMPK activation by this pathway represents a key mechanism in the prevention of insulin resistance and type 2 diabetes.
MOTS-c improves insulin sensitivity, promotes glucose utilization, inhibits oxidative stress, and activates NF-κB to suppress inflammatory signaling. In aged mice, exogenous MOTS-c administration improved physical performance and metabolic profiles through increased NAD⁺ availability and modulation of SIRT1 and SIRT3 sirtuin pathways — both essential regulators of mitochondrial function and cellular stress resistance.
The aging connection is direct: circulating MOTS-c levels decline progressively with age in humans, linking the peptide mechanistically to the metabolic deterioration associated with aging rather than merely correlating with it. Population studies associate MOTS-c with exceptional human longevity, and the data suggest it preserves metabolic flexibility and energy homeostasis in older individuals by countering the mitochondrial functional decline that accumulates over time. Exercise increases MOTS-c expression in both skeletal muscle and plasma, positioning it as a natural exercise mimetic that activates AMPK and NRF2 signaling through physiological mechanisms — a finding that raises interesting questions about the relationship between exercise-induced peptide release and the systemic metabolic benefits of physical activity.
Summary of Coverage
Of the twelve compounds in the broader reclassified stack, peer-reviewed evidence exists in the current knowledge base for seven: BPC-157, TB-500, GHK-Cu, Semax, Dihexa, KPV, and MOTS-c. Taken together, these compounds span tissue repair, neurological protection, immune modulation, and metabolic longevity. BPC-157, GHK-Cu, KPV, and MOTS-c carry particularly dense mechanistic literature. The remaining five — DSIP, LL-37, Epitalon, PEG-MGF, and Melanotan II — fall outside the current knowledge base and cannot be addressed with source-verified claims.
A consistent theme across the seven documented compounds is the gap between preclinical depth and human clinical evidence. The animal model data are, in several cases, extensive and mechanistically detailed. Confirmed human efficacy data, with the partial exceptions of Semax (stroke recovery) and GHK-Cu (skin studies), remain limited. That distinction matters when interpreting what the current evidence supports.